Bioregnum, Surveys

An introduction to the Endpoints 100

John Carroll, Editor

I’m well into a new project at Endpoints that I’d like to tell you about. It’s called the Endpoints 100. (Update: List of executives is at the bottom of this article.)

For the 14 or so years that I’ve covered biotech on a daily basis, I’ve seen some dramatic shifts in biotechs’ access to capital, attitudes about regulatory conditions for new drug approvals (on both sides of the Atlantic), views on gender diversity, along with a whole new focus on drug pricing and the future of the industry. Usually, these trends and attitudes are all tracked in retrospective analyses.

The Endpoints 100 is aiming at keeping a finger on the pulse of the industry, to detect changes — positive or negative — as they occur.

Over the last 10 days I’ve reached out to about 50 biotech CEOs who have agreed to participate. By the end of the month, I’ll have the rest of the group in place; an invitation-only affair that will bring together a broad cross section of top industry executives from small and large companies. They’ll be geographically diverse, though you can expect a lot of East Coast/West Coast, UK and continental execs in the mix. The vast majority, though not all, will be CEOs.

From this group I plan to gather responses for a quarterly confidence survey on biotech, offering a collective expression on the mood of the industry as we journey through one of the most critical passages faced in drug development. It’s also a resource for me to get some direct feedback on Endpoints as my partner Arsalan Arif and I craft this niche biotech news company over the coming year. And I’ll be asking a monthly poll question for the group.

There is one requirement: Endpoints 100 members need to be regular Endpoints readers. That doesn’t mean reading everything from top to bottom (who does that with any publication?). But in order to participate, you’ll need to be conversant with our coverage. (Here’s our dedicated subscription page. There’s never any cost to receive Endpoints. We’re looking for involvement, not cash.)

If you’d like to nominate someone, drop me a line. Just remember, though, that many are called, few are chosen. It’s going to take some balancing to get the right group together.

Look for the first survey in September. And if you have any questions, you can find me at:

– John Carroll

Update: Here is the list of current Endpoints 100 executives.

Andrea Pfeifer AC Immune
Ron Cohen Acorda
Rick Orr Adynxx
Mary Szela Aegerion Pharmaceuticals
David Schenkein Agios
Richard Pops Alkermes
Alexey Margolin Allena Pharmaceuticals
John Maraganore Alnylam
John Crowley Amicus
Mike Grey Amplyx
Hamza Suria AnaptysBio
Norbert Riedel Aptinyx
Joe Payne Arcturus Therapeutics
Tim Van Hauwermeiren Argenx
Bruce Booth Atlas Venture
Tito Serafini Atreca
Natalie Holles Audentes Therapeutics, Inc.
Jay Lichter Avalon Ventures
Carmine N. Stengone Avelas Biosciences, Inc.
Robert Connelly Axcella (Pronutria)
Howard Liang BeiGene
Jean-Jacques Bienaimé BioMarin Pharmaceutical
Jeffrey Albers Blueprint Medicines
Andrew J. Phillips C4 Therapeutics
Gregg Sando Cell Medica
Prabhavathi Fernandes Cempra
Art Krieg Checkmate Pharmaceuticals
Jeff Stein Cidara
Laura Shawver Cleave Bio
Doug Williams Codiak
Keith Dionne Constellation Pharma
Yuval Cohen Corbus Pharma
ROBERT I. BLUM Cytokinetics, Inc.
Sean McCarthy CytomX Therapeutics
Steve Holtzman Decibel Therapeutics
Ryan Watts Denali
Kevin Judice DiCE Molecules
Annalisa Jenkins Dimension Therapeutics
Geraldine Hamilton Emulate
Tim Mayleben Esperion
David Giljohann Exicure
Alexander Pasteur F-Prime Capital Partners
John Haurum F-star
Greg Verdine Fog Pharma
Sander Slootweg Forbion Capital Partners
Steve Tregay Forma Therapeutics
Michael Pellini Foundation Medicine
Robert Gould Fulcrum Therapeutics
Mark Velleca G1 Therapeutics
Pierluigi Paracchi GENENTA Science
Chip Clark Genocea Biosciences
Helen Torley Halozyme
Malcolm Weir Heptares
Rich Heyman Heyman Biotech
Russell Herndon Hydra Biosciences
Eliot Forster Immunocore
Hervé Hoppenot Incyte
Nessan Bermingham Intellia Therapuetics
Peter Hecht Ironwood
Kim Cobleigh Drapkin Jounce Therapeutics
Cameron Durrant KaloBios
Arie Belldegrun Kite Pharma
Troy Wilson Kura Oncology
Paul Sekhri Lycera Corp.
Kees Been Lysosomal Therapeutics
Denise Scots-Knight Mereo Biopharma
Anna Protopapas Mersana Therapeutics
Julia Owens Millendo
Chuck Baum Mirati Therapeutics
Stephane Bancel Moderna
Praveen Tipirneni Morphic Therapeutic
Tassos Gianakakos MyoKardia
George P. Vlasuk Navitor Pharmaceuticals, Inc.
David Mott NEA
Jeff Jonker NGM Bio
Don Nicholson Nimbus Therapeutics
Jon Congleton Nivalis Therapeutics
Clifford J. Stocks OncoResponse
Jeremy Levin Ovid Therapeutics
Bernard Coulie Pliant Therapeutics
Kevin Bitterman Polaris Partners
Dale Schenk Prothena
John Beadle PsiOxus
Alan Auerbach Puma
Douglas Treco Ra Pharmaceuticals
Robert Ward Radius
Olav Hellebø ReNeuron Group plc
Robert Coffin Replimune
Clay Siegall Seattle Genetics
Glenn Nedwin Second Genome
Werner Cautreels Selecta
Antoine Papiernik Sofinnova
Armon Sharei SQZ Therapeutics
Glyn Edwards Summit Therapeutics plc
Detlev Biniszkiewicz Surface Oncology
Kate Bingham SV Life Sciences
Nancy Simonian Syros Pharmaceuticals
Lonnie Moulder Tesaro
Mary Lynne Hedley Tesaro
Eduardo Bravo Tigenix, SAU
Maxine Gowen Trevena
Niclas Stiernholm Trillium Therapeutics
Bernat Olle Vedanta
Laurence Reid Warp Drive Bio
Steve Yang WuXi AppTec
Rachel King GlycoMimetics

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->